APR 0 6 2006 U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Jeffrey V. Ravetch

Serial No.: 09/834,321 Group Art Unit: 1644

Filing Date: April 13, 2001 Examiner: Michail A. Belyavskyi

For: ENHANCEMENT OF ANTIBODY-MEDIATED IMMUNE RESPONSES

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

	This Information Disclosure Statement is being filed:		
	within three months of the filing date of the patent application.		
	within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.		
	before the mailing date of a first Office Action on the merits.		
\boxtimes	after the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:		
	the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);		

		the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or				
		No fee is owed by the applicant(s).				
	Statem Final S C.F.R.	In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with \Box the first or \Box second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.				
	after the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously with, the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), a Petition requesting consideration of the Information Disclosure Statement and the Petition Fee of \$130.00 set forth in 37 C.F.R. § 1.17(i)(1) (see "Statement," "Petition," and "Fees" below).					
\boxtimes	Copies of references listed on the attached PTO Form SB/08B, formerly known as PTO Form 1449 are enclosed herewith					
	EXCE	EPT THAT:				
		In view of the voluminous nature of references @@, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.				
		In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.				
		Copies of references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 were previously cited by or submitted to the U.S. Patent and Trademark Office in parent application Serial No filed on				
		If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.				

Statement under 37 C.F.R. § 1.97(e	:))
------------------------------------	----	---

M	The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.			
Petitio	n			
	Applicant(s) hereby petitions the Commissioner to consider the references listed in this Information Disclosure Statement, on the enclosed PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449, and the examination of the above-identified patent application.			
Fees				
\boxtimes	No Fee is owed by the applicant(s).			
	The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. $\S 1.17(p)$ is enclosed herewith.			
	The Petition Fee of \$130.00 under 37 C.F.R. § 1.17(i)(1) is enclosed herewith.			
Metho	d of Payment of Fees			
	Attached is a check in the amount of \$ This form is submitted in duplicate.			
	Charge Deposit Account No. 50-1275 in the amount of $\$$. This form is submitted in duplicate.			
\boxtimes	Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.			
	No fee or Statement is required under 37 C.F.R. § 1.97(b).			

Respectfully submitted,

Dated: April 6, 2006

Mark DeLuca

Registration No. 33,229

COZEN O'CONNOR, P.C. 1900 Market Street

Philadelphia, PA 19103 Telephone: 215.665.5592 Facsimile: 215.701.2100

PTO/SB/08B(07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of | 1

Complete if Known Application Number 09/834,321 Filing Date April 13, 2001 First Named Inventor Jeffrey V. Ravetch Art Unit 1644 Michail A. Belyavskyi Examiner Name Attorney Docket Number RFU0001-100

(Use as many sheets as necessary)

Substitute for form 1449B

Sheet

NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of T² Cite the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Examiner No.1 number(s), publisher, city and/or country where published. Initials * HOUGHTON AN and SCHEINBERG DA, "Monoclonal Antibody Therapies - a 'Constant' Threat to Cancer', NATURE MEDICINE, Vol. 6, No. 4, April 2000, pages 373-374

Examiner	Date	
Signature	Considered	

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance